Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)

Trial Profile

Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)

Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Teplizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2012 Actual patient number is 4 according to ClinicalTrials.gov.
    • 20 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top